A clinical-stage biopharmaceutical company..

                        ..on track to fundamentally change the course of radiation therapy for cancer patients, worldwide.

Proprietary Technology 

Our technology and drug candidates have the potential to significantly reduce radiation toxicity in newly diagnosed cancer patients undergoing Radiation Therapy, as well as cancer survivors who have returned for more treatment, which includes Radiation Therapy.

 

Designed to be effective without the risk of interfering with the efficacy of the targeted therapy dosage:

 

     WILL prevent or mitigate damage to the skin and internal tissue during radiotherapy 

 

     WILL NOT impair the effectiveness of any radiation treatment on the patient's cancer cells

Market Size 

Some of the adverse side effects of radiation treatment include skin burns, blistering, permanent scarring and damage to internal non-cancer healthy tissue.

 

The medical care for these side effects is estimated at $3 billion annually in the United States.7,8

 

"The Web's Free ICD-9-CM Medical Coding Reference.” ICD9data.com. ICD9Data, Web. 28 September 2018.

“Healthcare Cost and Utilization Project (HCUP).” Ahrq.gov.com. Agency for Healthcare Research and Quality, July 2017.  Web. 28 September 2018.

Interests and Demand from Oncologists, Physicians and Healthcare Professionals

Physicians, patients, nonprofit organizations, hospitals, insurance companies and advocates for cancer patient support programs are familiar with the economic costs and wide ranging effects which the damage to normal tissue causes the patients whom are in treatment for their cancer.

Successfully Completed Pre-Clinical Studies

The proposed drugs generated from BioCurity's technology have been preclinically tested for multiple cancers including Breast, Lung, Head & Neck, Prostate and Colorectal Cancer.

 

The delivery system of the proposed drugs:

 

Topical: To prevent or mitigate radiation damage to the skin [radiation dermatitis] 

 

Intravenous [IV]: For protection of the internal tissue[s] against radiation damage

Highlights and Key Milestones

  • Consultants and Advisors are MDs, PhDs, MBAs, with Biotech Experience
     
  • Successful Track Record Clinical Development/Cancer CRO
     
  • Business Licensing with Big Pharma-Deals Closed
     
  • FDA and Global Regulatory Experience 
     
  • GMP Manufacturing Oversight
     
  • Maximizing Value of Assets for Shareholders-Exits
     
  • High Quality Committed Consultants with Fair Pricing
     
  • Competitive current valuation for investment

     
    • ​​Headquartered in Jupiter, Florida
  • Large well-defined market of unmet clinical need for cancer patients who require radiation therapy
     
  • 7 issued US patents with a fully paid non-royalty, freely transferable license for its technology
     
  • Additional International patent claims allowed and pending
     
  • PhD, MD and Key Opinion Leader input
     
  • Management team bringing over 20+ years of cancer treatment research, biotechnology
    distribution and corporate governance 

     
  • FDA Initial Drug Application (IND) submission pathway

     
    • Delaware Corporation
      [Audited Financial Statements]

       
Print Print | Sitemap
© 2020 BioCurity Pharmaceuticals Inc. All Rights Reserved.